Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx Corp reported third quarter 2025 revenue of $21.5 million, marking a 5% year-over-year growth driven by the increasing adoption of its Zephyr Endobronchial Valve. The company maintained a solid 75% gross margin, with gross profit improving to $16.1 million, while slightly narrowing its net loss to $14 million, suggesting effective cost management and a commitment to operational efficiency. With ongoing international expansion and disciplined investment in revenue-generating initiatives, alongside advancements in their pipeline and leadership, Pulmonx is well-positioned for sustained growth in the evolving medical technology sector.

Bears say

Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, marking a decline from Q2's $23.9 million and indicating a slower revenue growth trajectory, which contributed to management's guidance cut for the year to $90 million–$92 million. The company is experiencing execution risks in product models alongside challenges related to product mix and conversion timing, leading to pressures on both top-line growth and gross margins, which fell from 72% in Q2. A management transition with the return of Glen French as CEO and the appointment of Derrick Sung as COO/CFO further complicates the company's operational stability, impacting investor confidence.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.